Insulin delivery by injection in children and adolescents with diabetes

Pediatric Diabetes

Volumn 12, Issue 5, 2011, Pages 518-526

  Hanas, Ragnar ^a   de Beaufort, Carine ^b   Hoey, Hilary ^c   Anderson, Barbara ^d  

^a UDDEVALLA HOSPITAL   (Sweden)

^b DECCP   (Luxembourg)

^c ADELAIDE AND MEATH HOSPITAL   (Ireland)

^d BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

Adolescents; Children; Insulin; Insulin pen; Type 1 diabetes

Indexed keywords

GLUCOSE; INSULIN; NEUTRAL INSULIN;

ACCURACY; ADOLESCENT; BLOOD GLUCOSE MONITORING; CHILD; CONTINUOUS INFUSION; DEVICE; DIABETES MELLITUS; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; EVIDENCE BASED MEDICINE; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HEALTH SURVEY; HUMAN; HYPOGLYCEMIA; INJECTION; INJECTION SITE PAIN; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN PUMP; INSULIN TREATMENT; MEMORY; NON INSULIN DEPENDENT DIABETES MELLITUS; PATIENT COMPLIANCE; PATIENT SELECTION; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; RISK BENEFIT ANALYSIS; SYRINGE; TREATMENT OUTCOME; VISUAL ANALOG SCALE;

ADOLESCENT; CHILD; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; HUMANS; HYPOGLYCEMIC AGENTS; INJECTIONS; INSULIN; INSULIN INFUSION SYSTEMS; PARENTS; PATIENT COMPLIANCE; PATIENT SATISFACTION; QUALITY OF LIFE; SYRINGES;

EID: 79960894576     PISSN: 1399543X     EISSN: 13995448     Source Type: Journal    
DOI: 10.1111/j.1399-5448.2010.00731.x     Document Type: Review

References (75)

1. Hanas R, Ludvigsson J. Experience of pain from insulin injections and needle-phobia in young patients with IDDM. Pract Diabetes Int 1997: 14: 95-99.
2. Graff MR, McClanahan MA. Assessment by patients with diabetes mellitus of two insulin pen delivery systems versus a vial and syringe. Clin Ther 1998: 20: 486-496.
3. Mollema ED, Snoek FJ, Heine RJ, van der Ploeg HM. Phobia of self-injecting and self-testing in insulin-treated diabetes patients: opportunities for screening. Diabet Med 2001: 18: 671-674.
4. Pfützner A, Asakura T, Sommavilla B, Lee W. Insulin delivery with FlexPen: dose accuracy, patient preference and adherence. Expert Opin Drug Deliv 2008: 5: 915-925.
5. Asakura T, Seino H, Nakano R et al. A comparison of the handling and accuracy of syringe and vial versus prefilled insulin pen (FlexPen). Diabetes Technol Ther 2009: 11: 657-661.
6. Stockl K, Ory C, Vanderplas A et al. An evaluation of patient preference for an alternative insulin delivery system compared to standard vial and syringe. Curr Med Res Opin 2007: 23: 133-146.
7. Rex J, Jensen KH, Lawton SA. A review of 20 years' experience with the NovoPen family of insulin injection devices. Clin Drug Investig 2006: 26: 367-401.
8. Gnanalingham MG, Newland P, Smith CP. Accuracy and reproducibility of low dose insulin administration using pen-injectors and syringes. Arch Dis Child 1998: 79: 59-62.
9. Lombardo F, Salzano G, Messina MF, De LF. Compliance and administration methods in management of type 1 diabetes. Acta Biomed 2005: 76 (Suppl. 3): 66-69.
10. Hanel H, Weise A, Sun W, Pfutzner JW, Thome N, Pfutzner A. Differences in the dose accuracy of insulin pens. J Diabetes Sci Technol 2008: 2: 478-481.
11. Asamoah E. Insulin pen-the "iPod" for insulin delivery (why pen wins over syringe). J Diabetes Sci Technol 2008: 2: 292-296.
12. Summers KH, Szeinbach SL, Lenox SM. Preference for insulin delivery systems among current insulin users and nonusers. Clin Ther 2004: 26: 1498-1505.
13. Keith K, Nicholson D, Rogers D. Accuracy and precision of low-dose insulin administration using syringes, pen injectors, and a pump. Clin Pediatr (Phila) 2004: 43: 69-74.
14. Lee WC, Balu S, Cobden D, Joshi AV, Pashos CL. Medication adherence and the associated health-economic impact among patients with type 2 diabetes mellitus converting to insulin pen therapy: an analysis of third-party managed care claims data. Clin Ther 2006: 28: 1712-1725.
15. Dunning T. Insulin delivery devices. Aust Prescr 2002: 25: 136-138.
16. Bangstad HJ, Danne T, Deeb L, Jarosz-Chobot P, Urakami T, Hanas R. Insulin treatment in children and adolescents with diabetes. Pediatr Diabetes 2009: 10 (Suppl. 12): 82-99.
17. Hicks D. Insulin-delivery devices. Prof Nurse 2003: 18: 315-316.
18. Ignaut DA, Venekamp WJ. HumaPen Memoir: a novel insulin-injecting pen with a dose-memory feature. Expert Rev Med Devices 2007: 4: 793-802.
19. Kaufman KR, ed. Medical Management of Type 1 Diabetes. USA: American Diabetes Association, 2008.
20. Reimer T, Hohberg C, Pfutzner AH, Jorgensen C, Jensen KH, Pfutzner A. Intuitiveness, instruction time, and patient acceptance of a prefilled insulin delivery device and a reusable insulin delivery device in a randomized, open-label, crossover handling study in patients with type 2 diabetes. Clin Ther 2008: 30: 2252-2262.
21. Maia FF, Araujo LR. [Insulin pen injector for the treatment of type 1 diabetes mellitus]. J Pediatr (Rio J) 2002: 78: 189-192.
22. Peyrot M, Aanstoot H-J. Parent-reported social, psychological, and health care factors associated with youth self-care success in the Multi-national DAWN Youth Survey. Pediatr Diabetes 2008: 9 (Suppl. 10): 28.
23. Aanstoot HJ, Anderson B, Danne T et al. Outcomes of the DAWN Youth Summits of 2007 and 2008. Pediatr Diabetes 2009: 10 (Suppl. 13): 21-27.
24. Morris AD, Boyle DI, McMahon AD, Greene SA, MacDonald TM, Newton RW. Adherence to insulin treatment, glycaemic control, and ketoacidosis in insulin-dependent diabetes mellitus. The DARTS/ MEMO Collaboration. Diabetes Audit and Research in Tayside Scotland. Medicines Monitoring Unit. Lancet 1997: 350: 1505-1510.
25. Weintrob N, Benzaquen H, Galatzer A et al. Comparison of continuous subcutaneous insulin infusion and multiple daily injection regimens in children with type 1 diabetes: a randomized open crossover trial. Pediatrics 2003: 112: 559-564.
26. Jarosz-Chobot P, Guthrie DW, Otto-Buczkowska E, Koehler B. Self-care of young diabetics in practice. Med Sci Monit 2000: 6: 129-132.
27. Olinder AL, Kernell A, Smide B. Missed bolus doses: devastating for metabolic control in CSII-treated adolescents with type 1 diabetes. Pediatr Diabetes 2009: 10: 142-148.
28. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998: 352: 837-853.
29. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA. 10-Year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008: 359: 1577-1589.
30. Birkebaek NH, Solvig J, Hansen B, Jorgensen C, Smedegaard J, Christiansen JS. A 4-mm needle reduces the risk of intramuscular injections without increasing backflow to skin surface in lean diabetic children and adults. Diabetes Care 2008: 31: e65.
31. Hirsch LJ, Gibney MA, Albanese J et al. Comparative glycemic control, safety and patient ratings for a new 4 mm × 32G insulin pen needle in adults with diabetes. Curr Med Res Opin 2010: 26: 1531-1541.
32. Diglas J, Feinböck C, Winkler F et al. Reduced pain perception with an automatic injection device for use with an insulin pen. Horm Metab Res 1998: 50: A10.
33. Niskanen L, Jensen LE, Rastam J, Nygaard-Pedersen L, Erichsen K, Vora JP. Randomized, multinational, open-label, 2-period, crossover comparison of biphasic insulin aspart 30 and biphasic insulin lispro 25 and pen devices in adult patients with type 2 diabetes mellitus. Clin Ther 2004: 26: 531-540.
34. Korytkowski M, Bell D, Jacobsen C, Suwannasari R. A multicenter, randomized, open-label, comparative, two-period crossover trial of preference, efficacy, and safety profiles of a prefilled, disposable pen and conventional vial/syringe for insulin injection in patients with type 1 or 2 diabetes mellitus. Clin Ther 2003: 25: 2836-2848.
35. Asakura T, Seino H, Kageyama M, Yohkoh N. Evaluation of injection force of three insulin delivery pens. Expert Opin Pharmacother 2009: 10: 1389-1393.
36. Penfornis A, Horvat K. Dose accuracy comparison between SoloSTAR and FlexPen at three different dose levels. Diabetes Technol Ther 2008: 10: 359-362.
37. Asakura T, Seino H, Kageyama M, Yohkoh N. Dosing accuracy of two insulin pre-filled pens. Curr Med Res Opin 2008: 24: 1429-1434.
38. Haak T, Edelman S, Walter C, Lecointre B, Spollett G. Comparison of usability and patient preference for the new disposable insulin device Solostar versus Flexpen, lilly disposable pen, and a prototype pen: an open-label study. Clin Ther 2007: 29: 650-660.
39. Piscopo MA, Chiesa G, Bonfanti R, Viscardi M, Meschi F, Chiumello G. Quality of life and new devices in the management of type 1 diabetes in children and adolescents. Acta Biomed 2003: 74 (Suppl. 1): 21-25.
40. Tubiana-Rufi N, Levy-Marchal C, Mugnier E, Czernichow P. Long term feasibility of multiple daily injections with insulin pens in children and adolescents with diabetes. Eur J Pediatr 1989: 149: 80-83.
41. Lteif AN, Schwenk WF. Accuracy of pen injectors versus insulin syringes in children with type 1 diabetes. Diabetes Care 1999: 22: 137-140.
42. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993: 329: 977-986.
43. Bohannon NJ. Insulin delivery using pen devices. Simple-to-use tools may help young and old alike. Postgrad Med 1999: 106: 57-58, 61-64, 68.
44. Venekamp WJ, Kerr L, Dowsett SA et al. Functionality and acceptability of a new electronic insulin injection pen with a memory feature. Curr Med Res Opin 2006: 22: 315-325.
45. Olsen BS, Lilleøre SK, Korsholm CN, Kracht T. NovoPen Echo® for the delivery of insulin: a comparison of usability, functionality and preference among pediatric subjects, their parents and healthcare professionals. J Diabetes Sci Technol 2010. In press.
46. von Mach MA, Meyer S, Omogbehin B, Kann PH, Weilemann LS. Epidemiological assessment of 160 cases of insulin overdose recorded in a regional poisons unit. Int J Clin Pharmacol Ther 2004: 42: 277-280.
47. Jacombs J. Every child matters? Children with type 1 diabetes are being let down by lack of support in school. A report by the UK Children with Diabetes Advocacy Group investigating the range of contemporary educational experiences of children with diabetes at school in the UK. 2007.
48. Hanas R. Type 1 Diabetes in Children, Adolescents and Young Adults. London, UK: Class Publishing, 2009.
49. Danne T, Battelino T, Kordonouri O et al. A cross-sectional international survey of continuous subcutaneous insulin infusion in 377 children and adolescents with type 1 diabetes mellitus from 10 countries. Pediatr Diabetes 2005: 6: 193-198.
50. Klinkert C, Bachran R, Heidtmann B, Grabert M, Holl RW. Age-specific characteristics of the basal insulin-rate for pediatric patients on CSII. Exp Clin Endocrinol Diabetes 2008: 116: 118-122.
51. Phillip M, Battelino T, Rodriguez H, Danne T, Kaufman F. Use of insulin pump therapy in the pediatric age-group: consensus statement from the European Society for Paediatric Endocrinology, the Lawson Wilkins Pediatric Endocrine Society, and the International Society for Pediatric and Adolescent Diabetes, endorsed by the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2007: 30: 1653-1662.
52. Nabhan ZM, Kreher NC, Greene DM, Eugster EA, Kronenberger W, Dimeglio LA. A randomized prospective study of insulin pump vs. insulin injection therapy in very young children with type 1 diabetes: 12-month glycemic, BMI, and neurocognitive outcomes. Pediatr Diabetes 2009: 10: 202-208.
53. Froisland DH, Solevag AL, Markestad T. [Insulin pump for treatment of children and adolescents with diabetes]. Tidsskr Nor Laegeforen 2009: 129: 1094-1097.
54. Berhe T, Postellon D, Wilson B, Stone R. Feasibility and safety of insulin pump therapy in children aged 2 to 7 years with type 1 diabetes: a retrospective study. Pediatrics 2006: 117: 2132-2137.
55. Nimri R, Weintrob N, Benzaquen H, Ofan R, Fayman G, Phillip M. Insulin pump therapy in youth with type 1 diabetes: a retrospective paired study. Pediatrics 2006: 117: 2126-2131.
56. Willi SM, Planton J, Egede L, Schwarz S. Benefits of continuous subcutaneous insulin infusion in children with type 1 diabetes. J Pediatr 2003: 143: 796-801.
57. Sulli N, Shashaj B. Long-term benefits of continuous subcutaneous insulin infusion in children with type 1 diabetes: a 4-year follow-up. Diabet Med 2006: 23: 900-906.
58. Ahern JA, Boland EA, Doane R et al. Insulin pump therapy in pediatrics: a therapeutic alternative to safely lower HbA1c levels across all age groups. Pediatr Diabetes 2002: 3: 10-15.
59. Plotnick LP, Clark LM, Brancati FL, Erlinger T. Safety and effectiveness of insulin pump therapy in children and adolescents with type 1 diabetes 1681. Diabetes Care 2003: 26: 1142-1146.
60. Juliusson PB, Graue M, Wentzel-Larsen T, Sovik O. The impact of continuous subcutaneous insulin infusion on health-related quality of life in children and adolescents with type 1 diabetes. Acta Paediatr 2006: 95: 1481-1487.
61. Fox LA, Buckloh LM, Smith SD, Wysocki T, Mauras N. A randomized controlled trial of insulin pump therapy in young children with type 1 diabetes. Diabetes Care 2005: 28: 1277-1281.
62. Tamborlane WV, Fredrickson LP, Ahern JH. Insulin pump therapy in childhood diabetes mellitus: guidelines for use. Treat Endocrinol 2003: 2: 11-21.
63. McMahon SK, Airey FL, Marangou DA et al. Insulin pump therapy in children and adolescents: improvements in key parameters of diabetes management including quality of life. Diabet Med 2005: 22: 92-96.
64. Weintrob N, Shalitin S, Phillip M. Why pumps? Continuous subcutaneous insulin infusion for children and adolescents with type 1 diabetes 1131. Isr Med Assoc J 2004: 6: 271-275.
65. National Institute for Health and Clinical Excellence (NICE). Continuous subcutaneous insulin infusion for the treatment of diabetes mellitus 2008 (availablefrom).
66. Churchill JN, Ruppe RL, Smaldone A. Use of continuous insulin infusion pumps in young children with type 1 diabetes: a systematic review. J Pediatr Health Care 2009: 23: 173-179.
67. Hanas R. Reducing injection pain in children and adolescents with diabetes: a review of indwelling catheters. Pediatr Diabetes 2004: 5: 102-111.
68. Hanas R, Adolfsson P, Elfvin-Akesson K et al. Indwelling catheters used from the onset of diabetes decrease injection pain and pre-injection anxiety. J Pediatr 2002: 140: 315-320.
69. Hanas SR, Ludvigsson J. Metabolic control is not altered when using indwelling catheters for insulin injections. Diabetes Care 1994: 17: 716-718.
70. Burdick P, Cooper S, Horner B, Cobry E, McFann K, Chase HP. Use of a subcutaneous injection port to improve glycemic control in children with type 1 diabetes. Pediatr Diabetes 2009: 10: 116-119.
71. Chiasson JL, Ducros F, Poliquin-Hamet M, Lopez D, Lecavalier L, Hamet P. Continuous subcutaneous insulin infusion (Mill-Hill Infuser) versus multiple injections (Medi-Jector) in the treatment of insulin-dependent diabetes mellitus and the effect of metabolic control on microangiopathy. Diabetes Care 1984: 7: 331-337.
72. Houtzagers CM. Subcutaneous insulin delivery: present status. Diabet Med 1989: 6: 754-761.
73. Theintz GE, Sizonenko PC. Risks of jet injection of insulin in children. Eur J Pediatrics 1991: 150: 554-556.
74. Houtzagers CM, Visser AP, Berntzen PA, Heine RJ, van der Veen EA. The Medi-Jector II: efficacy and acceptability in insulin-dependent diabetic patients with and without needle phobia. Diabet Med 1988: 5: 135-138.
75. Schneider U, Birnbacher R, Schober E. Painfulness of needle and jet injection in children with diabetes mellitus. Eur J Pediatrics 1994: 153: 409-410.